Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

New Variants Also Make SARS-CoV2 A Moving Target

After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.

Hospital Covid patient
New data suggests the antibody therapies can have a big impact in preventing infection, or preventing at-risk individuals being hospitalized with severe COVID-19. • Source: Getty Images

Developed on unprecedented timelines similar to the COVID-19 vaccines, monoclonal antibody therapies – once seen as central to the fight against SARS-CoV-2 – have only played a limited role so far since the US emergency use approvals of Regeneron and Eli Lilly’s products.

Now armed with new data, and seeking expanded emergency use authorizations (EUAs), that looks set to change soon; but the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip